Abstract:Background: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) predicts the risk of malignancy for the different categories of the ultrasound-guided fine-needle aspiration biopsy (FNAB). The objective of this study is to investigate the efficiencies of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation test and the TBSRTC categories in distinguishing between benign and malignant thyroid nodules. Methods: In this study, 362 ultrasound-guided fine-needle aspiration (FNA) samples from 344 patients aged from 17 to 76 years old were retrospectively reviewed. The patients were classified into six groups (I-VI) according to the TBSRTC system. The amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was used to evaluate the BRAF V600E mutation level in total 362 samples. Among of the 344 patients, 128 patients (131 thyroid nodules) who underwent surgeries were followed by histopathological examination. The predictive values of the BRAF V600E mutation test and TBSRTC categories were evaluated in these 131 thyroid nodules. Results: The median ages of the patients in the TBSRTC IV-VI group were smaller than those in the TBSRTC I-III groups. The proportion of nodules over 1 cm was larger than it in the TBSRTC IV group compared to the other groups. Significant differences in BRAF V600E mutation were observed (P < .001) among these six groups. The sensitivity (89.57%) for the detection of malignant thyroid nodules, negative predictive value (NPV; 45.45%) for the detection of benign nodules, and accuracy (86.26%) for distinguishing between benign and malignant thyroid nodules increased by combining the BRAF V600E mutation test and TBSRTC system when compared with the BRAF V600E mutation test and TBSRTC system respectively. The BRAF V600E mutation test alone demonstrated the increased positive predictive value (PPV; 98.91%) and specificity (93.75%) for the detection of malignant thyroid nodules compared to the TBSRTC method (alone or in combination with the BRAF V600E method). Conclusion: In summary, significant differences in age, nodule diameter, and BRAF V600E mutation were noted among the six categories of the TBSRTC system. The combination of the BRAF V600E mutation test and TBSRTC system demonstrated increases in the NPV, sensitivity, and accuracy, while the BRAF V600E method proved superiority to the TBSRTC system with regard to the PPV and specificity.

Prognostic Prediction of BRAF(V600E) and Its Relationship with Sodium Iodide Symporter in Classic Variant of Papillary Thyroid Carcinomas.

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer with BRAF V600E Mutation.

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

BRAFV600E mutation and NIS expression in papillary thyroid carcinomas

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

Associations of the BRAF V600E Mutation with Sonographic Features in Patients with Papillary Thyroid Carcinoma

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

The Features of Contrast Enhanced Ultrasound and BRAF V600E in Papillary Thyroid Carcinoma.

BRAF mutation and sodium iodide symporter expression in papillary thyroid cancer

Value of Share Wave Elastography Combined with BRAFV600E in Predicting Central Lymph Nodes Metastasis of Papillary Thyroid Carcinoma

Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAFV600E Mutation

Poorer Prognosis and Higher Prevalence of BRAFV600E Mutation in Synchronous Bilateral Papillary Thyroid Carcinoma

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

[Clinical Role of BRAF V600E Mutation Testing in Thyroid Nodules].

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma

Noninferior Response in Braf(V600e) Mutant Nonmetastatic Papillary Thyroid Carcinoma to Radioiodine Therapy

The Predictive Accuracy of Fine Needle Aspiration and BRAF V600E Mutation in Diagnosis of Papillary Thyroid Carcinoma

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors

Prediction of Cervical Lymph Node Metastasis with Contrast-Enhanced Ultrasound and Association Between Presence of BRAFV600E and Extrathyroidal Extension in Papillary Thyroid Carcinoma